当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Laila Mahmoud Montaser
Coronaviruses attack the respiratory tracts in humans, causing a range of illnesses from the common cold to more serious,
fatal forms. Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need distress
syndrome (ARDS), although not as yet well studied in respiratory virus- for novel therapies. There is no vaccine or
specific treatment for COVID-19. Current available therapies fail in severe disease where the hallmark is the cytokine
storm induced by COVID-19 in the lung. Here I consider novel approaches to improve patient’s biological resistance
to COVID-19 using stem cells and to capture the therapeutic properties of stem cells with using nanotechnology. I
am handling to inspirit a therapy for use in hopes of slowing the propagation of the disease. Cell-based approaches,
primarily using mesenchymal stem cells (MSCs), have demonstrated safety and possible efficacy in patients with
the acute respiratory induced ARDS. MSCs are safe and can reverse severe critical disease with high potency may
representing an entirely new biological approach to treatment. Nanotechnology could provide advanced biomaterials
which can create a Nano scale extracellular environment capable of promoting the adhesion and proliferation of
stem cells and accelerating stem cell differentiation in a controlled manner. The investigation of stem cell based on
nanotechnology could provide new methods for stem cell therapy and tissue engineering. Nanotechnology may have
great potential to be of enormous help in the treatment of COVID-19. I am hopeful my outlook has implications for the
development of a novel drug for the treatment of this unprecedented pandemic.